We are pioneers: inventors and developers of an entirely new class of therapeutics.
As our name indicates, collaboration is in our DNA: within our team, with our partners, and with patients and providers. We build on deep trust, individual diversity, and shared passion to reach our common goal of surmounting the toughest challenges in medicine, including the treatment of cancer and other serious diseases.
Our long-term strategy leverages our in-house DARPin® design and development expertise combined with the capabilities of world-class partners to deliver a broad pipeline of innovative therapeutics.
Patrick Amstutz, Ph.D.Chief Executive Officer and Member of the Management Board, Member of the Board of Directors 
Michael Tobias Stumpp, Ph.D.Chief Operating Officer and Member of the Management Board
Andreas EmmeneggerChief Financial Officer and Member of the Management Board
Nicolas Leupin, M.D., Ph.D.Chief Medical Officer and Member of the Management Board
Ana Maria Mendes Cerdeira, Ph.D.VP, Strategic Planning and Portfolio Strategy
Seth LewisSVP Investor Relations, Communications and Strategy
Robert HendriksVP Finance
Julia Hepp, Ph.D.VP Partnering & Alliance
Julien Gander, LL.M.General Counsel, VP Legal
Alexander ZürcherSVP Development
Daniel Steiner, Ph.D.SVP ResearchResearch & Development Committee: Michael Vasconcelles (Chair), Agnete Fredriksen, Vito Palombella
Nomination & Compensation Committee: William Burns (Chair), Steven Holtzman, Michael Vasconcelles
Audit & Finance Committee: Sandip Kapadia (Chair), Dominik Höchli, Steven Holtzman
